Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Ho Hong

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Journal of Drugs in Dermatology : JDD|January 22, 2015
Optimizing the use of topical brimonidine in rosacea management: panel recommendationsEmil A Tanghetti, J Mark Jackson, Kevin Tate Belasco, et al.
American Journal of Clinical Dermatology|March 14, 2025
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 YearsRaj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
Journal of Cutaneous Medicine and Surgery|November 7, 2019
Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section IV: Consensus Statements on the Assessment and Management of Pediatric Atopic DermatitisPerla Lansang, Irene Lara-Corrales, James N Bergman, et al.
Dermatology and Therapy|September 12, 2021
Practical Management of Patients with Atopic Dermatitis on DupilumabKim A Papp, Chih-Ho Hong, M Perla Lansang, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Dermatology and Therapy|September 4, 2025
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic DermatitisMelinda J Gooderham, H Chih-Ho Hong, Di Wang, et al.
The British Journal of Dermatology|September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Journal of Drugs in Dermatology : JDD|January 22, 2015
Optimizing the use of topical brimonidine in rosacea management: panel recommendationsEmil A Tanghetti, J Mark Jackson, Kevin Tate Belasco, et al.
American Journal of Clinical Dermatology|March 14, 2025
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 YearsRaj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
Journal of Cutaneous Medicine and Surgery|November 7, 2019
Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section IV: Consensus Statements on the Assessment and Management of Pediatric Atopic DermatitisPerla Lansang, Irene Lara-Corrales, James N Bergman, et al.
Dermatology and Therapy|September 12, 2021
Practical Management of Patients with Atopic Dermatitis on DupilumabKim A Papp, Chih-Ho Hong, M Perla Lansang, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Dermatology and Therapy|September 4, 2025
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic DermatitisMelinda J Gooderham, H Chih-Ho Hong, Di Wang, et al.
The British Journal of Dermatology|September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Pageof 10